Canaccord Adams Starts Pharmion (PHRM) at Buy
More News related to PHRM
- Pharmion (PHRM) Shareholders Approve Acquisition by Celgene (CELG)
- Cohen's SAC Capital Moves Out of Pharmion (PHRM)
- Cohen's SAC Capital Wants A Higher Bid for Pharmion (PHRM)
- Cohen's SAC Capital Boosts Stake in Pharmion (PHRM) to 8.3%
- Cohen's SAC Capital Discloses 7% Stake in Merger Stock Pharmion (PHRM)
Canaccord Adams initiates coverage on Pharmion (Nasdaq: PHRM) with a Buy rating and $40 price target.
Analyst David Bouchey said, "Concerns that competition could erode sales and cap the growth for Vidaza and Thalidomide have depressed the share price. We feel these concerns are overblown and believe that PHRM shares are undervalued as a result." Bouchey also said, "We think there is about 60% upside potential to the current share price as Pharmion hits the following anticipated milestones: FDA approval for an IV form of Vidaza in Q4/06 or Q1/07, an EU filing for Thalidomide in Q1/07, an EU filing for Satraplatin in Q1/07, survival study results for Vidaza in Q3/07 and an EU filing for Vidaza in Q4/07."
Related Categories
New CoverageStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
